Jul 10, 2023
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
May 31, 2023
The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry. We are pleased to present the third volume of the Deal Makers of Japan - Exclusive Interviews with Japan’s best dealmakers,...
Apr 10, 2023
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Frist Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Feb 22, 2023
Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition, Protein Expression, RNA-Targeting Small Molecules, RNA Editing, and RNA-Mediated Protein and Transcriptome Regulation.
Jan 8, 2023
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Year In Review Report applies the latest data to analyze current activities in the life sciences deal landscape.
Oct 11, 2022
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
